Merck expands its capacity for the production of viral vectors and gene therapy

Merck announced the creation of the carlsbad (California, USA) a second enterprise for productive maintenance of the services we provide virus and gene therapy of BioReliance. It is assumed that the new commercial facility worth 100 million euros will be put into operation next year.

The Life Science company Merck in carlsbad produces a gene-therapy products for customers worldwide. Gene therapy is associated with the delivery of genetic material into cells of a patient for the correction of the mutated gene or redirect the immune cells to fight cancer. For the treatment of several diseases, including hemophilia and cancer, studies on the perspectives of using this technology.

According to the analysis of the international market, it is expected that the market for gene therapy, which was 1 billion dollars in 2018, will reach 2026 $ 10 billion.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]